- Main
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
- Swisher, Elizabeth M;
- Kwan, Tanya T;
- Oza, Amit M;
- Tinker, Anna V;
- Ray-Coquard, Isabelle;
- Oaknin, Ana;
- Coleman, Robert L;
- Aghajanian, Carol;
- Konecny, Gottfried E;
- O’Malley, David M;
- Leary, Alexandra;
- Provencher, Diane;
- Welch, Stephen;
- Chen, Lee-may;
- Wahner Hendrickson, Andrea E;
- Ma, Ling;
- Ghatage, Prafull;
- Kristeleit, Rebecca S;
- Dorigo, Oliver;
- Musafer, Ashan;
- Kaufmann, Scott H;
- Elvin, Julia A;
- Lin, Douglas I;
- Chambers, Setsuko K;
- Dominy, Erin;
- Vo, Lan-Thanh;
- Goble, Sandra;
- Maloney, Lara;
- Giordano, Heidi;
- Harding, Thomas;
- Dobrovic, Alexander;
- Scott, Clare L;
- Lin, Kevin K;
- McNeish, Iain A
- et al.
Published Web Location
https://doi.org/10.1038/s41467-021-22582-6Abstract
ARIEL2 (NCT01891344) is a single-arm, open-label phase 2 study of the PARP inhibitor (PARPi) rucaparib in relapsed high-grade ovarian carcinoma. In this post hoc exploratory biomarker analysis of pre- and post-platinum ARIEL2 samples, RAD51C and RAD51D mutations and high-level BRCA1 promoter methylation predict response to rucaparib, similar to BRCA1/BRCA2 mutations. BRCA1 methylation loss may be a major cross-resistance mechanism to platinum and PARPi. Genomic scars associated with homologous recombination deficiency are irreversible, persisting even as platinum resistance develops, and therefore are predictive of rucaparib response only in platinum-sensitive disease. The RAS, AKT, and cell cycle pathways may be additional modulators of PARPi sensitivity.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.
Main Content
Enter the password to open this PDF file:
-
-
-
-
-
-
-
-
-
-
-
-
-
-